A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

After Sarepta reported the death of a patient who had recently taken the gene therapy Elevydis, patient advocacy group Parent ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...

Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

While plenty of people are going green in honor of Saint Patrick's Day, one student at East Stroudsburg University is turning ...

—The initial signs of Duchenne muscular dystrophy in a 3 or 4-year-old child may be subtle, explains Dr. Alexandra Bonner of the Center for Pediatric Neurosciences at Cleveland Clinic.

Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach ...

Duchenne muscular dystrophy (DMD) is a genetic condition ... Each time a person who is a carrier of DMD has a child who is assigned male at birth, the child has a 50% chance of developing DMD.